EFFECTS OF N-ACETYLCYSTEIN ON HSCRP LEVEL IN ACUTE MYOCARDIAL INFARCTION PATIENTS RECEIVING FIBRINOLYTIC THERAPY

Abstract

EFFECTS OF N-ACETYLCYSTEIN ON HSCRP LEVEL IN ACUTE MYOCARDIAL  INFARCTION  PATIENTS RECEIVING FIBRINOLYTIC THERAPY

 

Savithri Indriani1, Ahmad Yasa1, Trisulo Wasyanto1

1Department of Cardiology and Vascular Medicine, Faculty of Medicine,

Universitas Sebelas Maret, RS Dr. Moewardi, Surakarta, Indonesia

 

Background: Worldwide, coronary heart disease (CHD) is a leading cause of death. Inflammation in CHD and acute myocardial infarction (AMI) is a trigger due to the formation of atheroma plaques in the coronary arteries. N-Acetylcysteine ​​(NAC) can prevent inflammation, remodeling and left ventricular dysfunction, interstitial fibrosis, and improve survival.

Objective: To determine the effect of NAC on hsCRP levels in patients with acute myocardial infarction who received fibrinolytic therapy.

Methods: This study was an experimental study with pre and post, single blind and randomization methods on the effect of NAC on hsCRP levels compared to controls carried out in July - August 2018 on the incidence of ST Elevation Myocardial Infarction (STEMI) came to Dr Moewardi Hospital and get fibrinolytic therapy.

Results: A total of 33 patients were included in this study, there were 15 patients (mean age 58.80 ± 8.54 years) of the control group and 18 patients (mean age 55.45 ± 9.92 years) the treatment group receiving additional therapy of NAC evervescent 600 mg three times a day for three days . This study showed that hsCRP levels after intervention in the control and treatment groups were significantly different with p = 0.001. The level of hsCRP in the control group after administration of NAC had a median of 114.50 mg / L (18.60 - 300.00) while in the treatment group had a median of 18.75 mg / L (5.50 - 102.90).

Conclusion: The addition of NAC 600 mg of therapy three times daily for 3 days can reduce hsCRP levels in patients with STEMI receiving fibrinolytic therapy compared to patients with acute myocardial infarction with ST segment elevation who did not receive additional NAC therapy.

Keywords: hsCRP, N-Acetylcysteine, acute myocardial infarction

.

 

PENGARUH N-ACETYLCYSTEIN TERHADAP HSCRP PADA PASIEN INFARK MIOKARD AKUT DENGAN ELEVASI SEGMEN ST YANG MENDAPAT TERAPI FIBRINOLITIK

 

Savithri Indriani1, Ahmad Yasa1, Trisulo Wasyanto1

Departemen Ilmu Penyakit Jantung dan Pembuluh Darah, Fakultas Kedokteran

Universitas Sebelas Maret, RS Dr. Moewardi, Surakarta, Indonesia

 

Latar Belakang: Di seluruh dunia, penyakit jantung koroner (PJK) merupakan penyebab utama kematian. Inflamasi pada PJK dan infark miokard akut (IMA) merupakan pemicu akibat terbentuknya plak ateroma pada arteri koroner. N-Acetylcysteine (NAC) dapat mencegah inflamasi, remodeling dan disfungsi ventrikel kiri, fibrosis interstisial, dan meningkatkan survival.

Tujuan: Untuk mengetahui pengaruh  NAC terhadap kadar hsCRP pada pasien infark miokard akut yang mendapatkan terapi fibrinolitik.

Metode:  Penelitian ini merupakan penelitian eksperimental dengan metode pre dan post, single blind dan randomisasi  mengenai pengaruh NAC terhadap kadar hsCRP dibandingkan dengan kontrol yang dilakukan pada bulan Juli - Agustus 2018 terhadap paien Infark Miokard Akut dengan Elevasi Segmen ST (IMA-EST) yang datang ke  Rumah Sakit Dr Moewardi dan mendapat terapi fibrinolitik.

Hasil: Sebanyak 33 pasien diikutsertakan pada penelitian ini, terdapat 15 pasien (rerata usia 58.80±8.54 tahun) kelompok kontrol dan 18 pasien (rerata usia 55.45±9.92 tahun) kelompok perlakuan yang mendapat terapi tambahan NAC evervescent 600 mg tiga kali sehari selama tiga hari.  Penelitian ini menunjukkan bahwa kadar hsCRP sesudah dilakukan intervensi pada kelompok kontrol dan perlakuan berbeda bermakna dengan nilai p = 0.001. Kadar hsCRP pada kelompok kontrol  sesudah pemberian NAC memiliki median 114.50 mg/L(18.60 – 300.00) sedangkan pada kelompok perlakuan memiliki median 18.75 mg/L(5.50 – 102.90).

Kesimpulan: Pemberian terapi tambahan NAC 600 mg tiga kali sehari selama 3 hari dapat menurunkan kadar hsCRP pada pasien infark miokard akut dengan elevasi segmen ST yang mendapat terapi fibrinolitik dibanding pasien infark miokard akut dengan elevasi segmen ST yang tidak mendapat terapi tambahan NAC.

Kata Kunci: hsCRP,  N-Acetylcysteine, infark miokard akut

Downloads

Download data is not yet available.

References

1. Hartley A, Marshall DC, Salciccioli JD, Sikkel
MB, Maruthappu M, Shalhoub J. Trends in mortality
from ischemic heart disease and cerebrovascular disease in Europe: 1980 to 2009. Circulation.
2016;133(20):1916-1926.
2. Townsend N, Wilson L, Bhatnagar P, Wickramasinghe
K, Rayner M, Nichols M. Cardiovascular
disease in Europe: Epidemiological update 2016.
Eur Heart J. 2016;37(42):3232-3245.
3. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart
Disease and Stroke Statistics-2015 Update : A Report
from the American Heart Association. Vol 131.; 2015.
4. Dharma S, Juzar DA, Firdaus I, Soerianata S. Acute
myocardial infarction system of care in the third
world. Neth Hear J. 2012;20(6):254-259.
5. White HD, Chew DP. Acute myocardial infarction.
Lancet. 2008;372(9638):570–584.
6. Packard RRS, Libby P. Inflammation in Atherosclerosis:
From Vascular Biology to Biomarker Discovery
and Risk Prediction. Clin Chem. 2007;54(1):24-
38.
7. Hansson G. Inflammation, Atherosclerosis,
and Coronary Artery Disease. N Engl J Med.
2005;352:1685-1695.
8. Kushner I. The Acute Phase Response. Curr Contents.
1982;40:16.
9. Liuzzo G, Biasucci LM, Gallimore JR, et al. Enhanced
inflammatory response in patients with
preinfarction unstable angina. J Am Coll Cardiol.
1999;34(6):1696-1703.
10. Tomoda H, Aoki N. Prognostic value of C-reactive
protein levels within six hours after the onset
of acute myocardial infarction. Am Heart J.
2000;140(2):324-328.
11. Makrygiannis SS, Ampartzidou OS, Zairis MN, et
al. Prognostic usefulness of serial c-reactive protein
measurements in st-elevation acute myocardial infarction.
Am J Cardiol. 2013;111(1):26-30.
12. Yesilbursa D, Serdar A, Senturk T, Serdar Z, SaÄŸ
S, Cordan J. Effect of N-acetylcysteine on oxidative
stress and ventricular function in patients with
myocardial infarction. Heart Vessels. 2006;21(1):33-
37.
13. Talasaz AH, Khalili H, Fahimi F, et al. Effects of
N-acetylcysteine on the cardiac remodeling biomarkers
and major adverse events following acute
myocardial infarction: A randomized clinical trial.
Am J Cardiovasc Drugs. 2014;14(1):51-61.
14. Pasupathy S, Tavella R, Grover S, et al. Early use of
N-Acetylcysteine (NAC) with Nitrate Therapy in Patients
Undergoing Primary Percutaneous Coronary
Intervention for ST-Segment Elevation Myocardial
Infarction Reduces Myocardial Infarct Size (The NACIAM
Trial). Circulation.2017;136(10):894-903.
15. O’Gara PT, Kushner FG, Ascheim DD, et al.
2013 ACCF/AHA guideline for the management
of ST-elevation myocardial infarction: a report of
the American College of Cardiology Foundation/
American Heart Association Task Force on Practice
Guidelines. J Am Coll Cardiol. 2013;61(4):e78-140.
16. Waard M, Velden J, Boontje N. Detrimental effect
of combined exercise training and eNOS overexpression
on cardiac function after myocardial infarction.
Am J Physiol Hear Circ Physiol. 2009;296(5):1513-
1523.
17. Zuin R, Palamidese a, Negrin R. High-dose N-acetylcysteine
in patients with exacerbations of chronic
obstructive pulmonary disease. Clin drug ….
2005;25(6):401-408. http://link.springer.com/article/
10.2165/00044011-200525060-00005.
18. Pinkus R, Weiner L, Daniel V. Role of oxidants and
antioxidants in the induction of AP-1, NF- κ B,
and glutathione S-transferase gene expression. J Biol
Chem. 1996;271:13422-13429.
19. Radomska D, Skopiñski P. N-acetylcysteine as an
anti-oxidant and anti-inflammatory drug and its
some clinical applications. Centr Eur J Immunol.
2012;37(1):57-66.
20. Sajkowska A, Wykretowicz A, Szczepanik A. Fibrinolytic
therapy and N-Acetylcysteine in the treatment
of patients with acute myocardial infarction:
its influence on authentic plasma hydroperoxide
levels and polymorphonuclear neutrophil oxygen
metabolism. Cardiology. 1999;91(1):60-65.
21. Westman P, Lipinski M, Luger D, et al. Inflammation
as a Driver of Adverse Left Ventricular Remodeling
After Acute Myocardial Infarction. JACC.
2016;67(17):2050-2060.
Published
2019-09-11
How to Cite
EFFECTS OF N-ACETYLCYSTEIN ON HSCRP LEVEL IN ACUTE MYOCARDIAL INFARCTION PATIENTS RECEIVING FIBRINOLYTIC THERAPY. (2019). Indonesian Journal of Cardiology, 39(4). https://doi.org/10.30701/ijc.v39i4.798